Gilead Sciences' Lenacapavir Provides 'Solid' Switching Opportunities for Current PrEP Users, RBC Says

Published on 11/06/2025 at 18:03

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Gilead Sciences, Inc.

Gilead Sciences Insider Sold Shares Worth $548,700, According to a Recent SEC Filing	07-15	MT
Sector Update: Health Care Stocks Fall Late Afternoon	07-15	MT
Sector Update: Health Care	07-15	MT
Gilead Sciences Reaches $202 Million Settlement Over Kickback Scheme Promoting HIV Drugs	07-15	MT
Ny ag James- my office and 48 ags secured $202 million from Gilead Sciences - X post	07-15	RE
Gilead Says Yeztugo Shows Broad Effectiveness, Tolerability for Diverse HIV Prevention	07-14	MT
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention At Ias 2025	07-14	CI
Global markets live: Tesla, Gilead, Kenvue, Amazon, Bayer…	07-14
ViiV expands licence to allow generic HIV treatment production for low-income countries	07-14	RE
WHO recommends Gilead's twice-yearly injection for HIV prevention	07-14	RE
WHO recommends Gilead's twice-yearly injection for HIV prevention	07-14	RE
World Health Organization recommends injectable Lenacapavir for HIV prevention	07-14	RE
Wall Street Retreats as Investors Monitor Tariffs Updates, Bank Earnings Loom	07-11	MT
Equity Markets Close Lower as Trade Tensions Escalate	07-11	MT
Sector Update: Health Care Stocks Retreat Late Afternoon	07-11	MT
Equity Markets Lower After US Treasury Budget Surplus in June	07-11	MT
Sector Update: Health Care	07-11	MT
Equity Markets Mostly Fall Intraday as Traders Track Tariff Updates	07-11	MT
HSBC Adjusts Price Target on Gilead Sciences to $91 From $93, Maintains Hold Rating	07-11	MT
Briacell's Bria-Imt(TM) demonstrates survival advantage over Trodelvy® and control group in metastatic breast cancer	07-11	RE
BriaCell Says Bria-IMT Outperforms Trodelvy in Phase 2 Metastatic Breast Cancer Trial	07-11	MT
Time To Grow PFL Fanbase, Revenue: CEO John Martin	07-11	MT
Nurix Therapeutics Fiscal Q2 Loss Narrows, Revenue More Than Triples; Shares Surge Premarket	07-10	MT
Major deals involving U.S. drugmakers and biotechs over the past decade	07-09	RE
Gilead finalizes agreement with global fund to accelerate access to Lenacapavir	07-09	RE

GILEAD SCIENCES, INC.

Stock

GILD

US3755581036

Market Closed - Nasdaq Other stock markets 21:00:00 15/07/2025 BST
109.06 ^USD	-2.70%

More quotes

Chart

Duration

Period

GILD: Dynamic Chart

Income Statement and Estimates

More financial data

Analysis / Opinion

Time To Grow PFL Fanbase, Revenue: CEO John Martin

More Strategies

Headlines

Rio Tinto posts strongest iron ore output since 2018 amid executive shake-up

What if we already knew the name of Apple's next CEO?

July 16, 2025 at 08:21 am

A Scandinavian consortium acquires Dalata for EUR1.4bn

July 15, 2025 at 03:04 pm

Mexican tomatoes: Made in the USA or higher prices, the Trump dilemma

July 15, 2025 at 02:56 pm

Meta to spend hundreds of billions on data centers

July 15, 2025 at 12:00 pm

Chinese growth exceeds expectations in second quarter, but uncertainties remain

July 15, 2025 at 11:56 am

Nvidia announces the return of its chips to China

July 15, 2025 at 11:49 am

The renovation of Fed's headquarters: a new means of pressure from White House on Jerome Powell

July 15, 2025 at 09:59 am

Google has halted OpenAI's acquisition of Windsurf

July 14, 2025 at 03:00 pm

Loro Piana (LVMH) placed under judicial supervision for one year for illegal subcontracting

July 14, 2025 at 02:00 pm

All our articles